Ground News

News from Globe Newswire

See all of Globe Newswire news coverage in one place. Discover how Globe Newswire’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 173 headlines written by Globe Newswire during the past 3 months.

The Ground News media bias check for Globe Newswire is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

If you want to know if Globe Newswire is credible or reliable, look no further. We rank Globe Newswire as High factuality. Find out more about our methodology here.

Information about Globe Newswire

Where is Globe Newswire located?Globe Newswire's Website Globe Newswire's Twitter Globe Newswire's Wikipedia

Media Bias Ratings

Average Bias Rating:

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Globe Newswire News

Donald Trump · United States

Trump Media shares surge after announcing expansion into financial services including crypto and ETFs

58% Center coverage: 45 sources

Trump Media and Technology Group announced Wednesday that it is expanding into financial services, including investment vehicles. Shares of the Truth Social parent company, which trade under the ticker DJT, jumped more than 15% in premarket trading.See the Story

Business

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio - Lantheus Holdings (NASDAQ:LNTH)

100% Center coverage: 3 sources

On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments. Evergreen is a clinical-stage radiopharmaceutical company that offers Contract Development and Manufacturing (CDMO) services, drug discovery, and the commercialization of proprietary products. This transacti…See the Story

Parkinson's Disease

What's Going On With Alterity Therapeutics Shares Thursday? - Alterity Therapeutics (NASDAQ:ATHE)

100% Center coverage: 2 sources

Alterity Therapeutics Limited (NASDAQ:ATHE) shares are moving higher on Thursday after the company reported topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy (MSA). ATH434 demonstrated clinically meaningful results in slowing early-stage multiple system atrophy and showed a favorable safety profile. There is currently no FDA-approved, disease altering treatment for MSA. The trial enrolled 77 adults …See the Story

News from Globe Newswire

News from Globe Newswire

Information about Globe Newswire

Media Bias Ratings

Factuality

Ownership

Top Globe Newswire News

Trump Media shares surge after announcing expansion into financial services including crypto and ETFs

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio - Lantheus Holdings (NASDAQ:LNTH)

What's Going On With Alterity Therapeutics Shares Thursday? - Alterity Therapeutics (NASDAQ:ATHE)

Latest News Stories

Topics Most Covered by Globe Newswire

Sources Covering Similar Topics

Breaking News Topics Related to Globe Newswire